The idea: send instructions, not the protein
An mRNA therapeutic does not deliver a finished drug. It delivers a message — a strand of messenger RNA — that your own cells read and translate into a protein. Encode the spike protein of a virus and the body makes that protein, sees it as foreign, and learns to defend against it: that is an mRNA vaccine. Encode a missing enzyme and, in principle, you supply a protein the patient cannot make for themselves.
Two properties define the modality. First, it is transient: the cell translates the mRNA for a while, then degrades it — there is no permanent change to your DNA, unlike gene therapy. That makes it safer for things like vaccines, but means repeat dosing for any lasting effect. Second, like a vaccine it has a short biological half-life, so the design goal is often a sharp, controlled burst of protein production.
Why the lipid nanoparticle is the real invention
Naked mRNA is fragile and negatively charged; injected on its own it is destroyed in minutes and cannot enter cells. The breakthrough that made mRNA practical was not the RNA chemistry alone but the lipid nanoparticle (LNP) that carries it. The LNP is a tiny fatty bubble that wraps the mRNA, protects it, slips it across the cell membrane, and then releases it inside.
- An ionizable lipid is neutral in the blood (gentle to tissues) but becomes positively charged in the acidic compartment inside the cell, helping the particle break open and release its cargo.
- A PEG-lipid coats the surface to control particle size and stop the bubbles from clumping.
- Cholesterol and a helper lipid give the particle the right stiffness and stability to survive until it reaches a cell.